日本高潮视频在线观看-亚洲中文字幕永不卡-精品亚洲一区二区三区-伦理片夜夜躁狠狠躁日日躁-日本最新免费不卡二区-国产精品口爆一区二区三区-av一区二区三区高清-大鸡巴疯狂抽插小穴视频-日韩中文国产在线观看免费视频

Your Good Partner in Biology Research

CCR7

CCR7全稱為C-C趨化因子受體7型,也被稱為CD197,是趨化因子受體家族的重要成員。CCR7通過(guò)與配體CCL19和CCL21結(jié)合,引導(dǎo)淋巴細(xì)胞定向遷移至次級(jí)淋巴器官,對(duì)維持免疫系統(tǒng)穩(wěn)態(tài)具有關(guān)鍵作用。CCR7在樹突狀細(xì)胞成熟過(guò)程中表達(dá)上調(diào),幫助抗原呈遞細(xì)胞精準(zhǔn)定位至淋巴結(jié),從而啟動(dòng)適應(yīng)性免疫應(yīng)答。臨床上,CCR7的異常表達(dá)與多種疾病密切相關(guān),在乳腺癌、黑色素瘤等惡性腫瘤中,癌細(xì)胞通過(guò)激活該受體實(shí)現(xiàn)淋巴結(jié)轉(zhuǎn)移;而在類風(fēng)濕性關(guān)節(jié)炎患者中,CCR7過(guò)度活化會(huì)促使炎癥細(xì)胞浸潤(rùn)關(guān)節(jié)滑膜。針對(duì)CCR7的藥物開(kāi)發(fā)聚焦于腫瘤免疫治療領(lǐng)域,已有小分子拮抗劑在動(dòng)物模型中成功阻斷腫瘤轉(zhuǎn)移,但進(jìn)入臨床階段的候選藥物仍較少。利用單克隆抗體阻斷CCR7-配體相互作用的新型療法,在治療自身免疫性疾病方面展現(xiàn)出潛在價(jià)值,相關(guān)研究正在從實(shí)驗(yàn)室向轉(zhuǎn)化醫(yī)學(xué)推進(jìn)。

熱銷產(chǎn)品

Recombinant Human C-C chemokine receptor type 7 (CCR7), partial (CSB-EP004846HU1)

驗(yàn)證數(shù)據(jù)

CSB-EP004846HU1

(Tris-Glycine gel) Discontinuous SDS-PAGE (reduced) with 5% enrichment gel and 15% separation gel.

CCR7 Antibody (CSB-PA004846LA01HU)

驗(yàn)證數(shù)據(jù)

CSB-PA004846LA01HU

Immunohistochemistry analysis of human lung tissue using CSB-PA004846LA01HU at dilution of 1:100

CSB-PA004846LA01HU

Immunocytochemistry analysis of human tonsil tissue using CSB-PA004846LA01HU at dilution of 1:100

CSB-PA004846LA01HU

Immunofluorescent analysis of Hela cells using CSB-PA004846LA01HU at dilution of 1:100 and Alexa Fluor 488-congugated AffiniPure Goat Anti-Rabbit IgG(H+L)

CCR7 Antibodies

CCR7 for Homo sapiens (Human)

CCR7 Proteins

CCR7 Proteins for Homo sapiens (Human)

CCR7 Proteins for Mus musculus (Mouse)

CCR7 Proteins for Bos taurus (Bovine)



×